{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T09:44:20Z","timestamp":1789465460397,"version":"build-2803163510"},"reference-count":13,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,15]]},"DOI":"10.1093\/ejhf\/xuag096","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T12:50:38Z","timestamp":1774443038000},"page":"535-537","source":"Crossref","is-referenced-by-count":0,"title":["MRA-induced eGFR decline\u2014causes, consequences, and context"],"prefix":"10.1093","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3278-2057","authenticated-orcid":false,"given":"Nicolas","family":"Girerd","sequence":"first","affiliation":[{"name":"CHRU de Nancy, Centre d'Investigations Cliniques Plurith\u00e9matique 1433, INSERM, Universit\u00e9 de Lorraine, INSERM U1116\u2014DCAC, and F-CRIN iNI-CRCT (Cardiovascular and Renal Clinical Trialists) , Nancy ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1411-4482","authenticated-orcid":false,"given":"Lars H","family":"Lund","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Karolinska Institutet, and Heart and Vascular and Neuro Theme, Karolinska University Hospital , Stockholm, 17177 ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"key":"2026091504191235600_xuag096-B1","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/S0140-6736(23)02408-X","article-title":"Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial","volume":"403","author":"Tuttle","year":"2024","journal-title":"Lancet"},{"key":"2026091504191235600_xuag096-B2","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1093\/ejhf\/xuag099","article-title":"Spironolactone, early acute eGFR changes, and clinical outcomes in patients with heart failure with preserved ejection fraction: insights from TOPCAT Americas","volume":"28","author":"Beldhuis","year":"2026","journal-title":"Eur J Heart Fail"},{"key":"2026091504191235600_xuag096-B3","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"key":"2026091504191235600_xuag096-B4","doi-asserted-by":"publisher","first-page":"CD007004","DOI":"10.1002\/14651858.CD007004.pub3","article-title":"Aldosterone antagonists for preventing the progression of chronic kidney disease","author":"Bolignano","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"2026091504191235600_xuag096-B5","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1002\/ejhf.2503","article-title":"Practical outpatient management of worsening chronic heart failure","volume":"24","author":"Girerd","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026091504191235600_xuag096-B6","doi-asserted-by":"publisher","first-page":"4583","DOI":"10.1093\/eurheartj\/ehaf457","article-title":"Kidney function trajectories before and after hospitalization for heart failure with reduced ejection fraction","volume":"46","author":"Kobayashi","year":"2025","journal-title":"Eur Heart J"},{"key":"2026091504191235600_xuag096-B7","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1002\/ejhf.3295","article-title":"How to tackle therapeutic inertia in heart failure with reduced ejection fraction. A scientific statement of the heart failure association of the ESC","volume":"26","author":"Savarese","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026091504191235600_xuag096-B8","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1002\/ehf2.13929","article-title":"Therapeutic inertia in the pharmacological management of heart failure with reduced ejection fraction","volume":"9","author":"Girerd","year":"2022","journal-title":"ESC Heart Fail"},{"key":"2026091504191235600_xuag096-B9","doi-asserted-by":"publisher","first-page":"3066","DOI":"10.1093\/eurheartj\/ehaf229","article-title":"Heart failure: the need for cardiologist-guided follow-up to improve outcomes","volume":"46","author":"Lund","year":"2025","journal-title":"Eur Heart J"},{"key":"2026091504191235600_xuag096-B10","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1002\/ejhf.1757","article-title":"Association between potassium level and outcomes in heart failure with reduced ejection fraction: a cohort study from the Swedish heart failure registry","volume":"22","author":"Cooper","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026091504191235600_xuag096-B11","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1002\/ejhf.1175","article-title":"Is hyperkalaemia in heart failure a risk factor or a risk marker? Implications for renin-angiotensin-aldosterone system inhibitor use","volume":"20","author":"Lund","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026091504191235600_xuag096-B12","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.1016\/j.jacc.2020.04.021","article-title":"Abnormalities of potassium in heart failure. JACC state-of-the-art review","volume":"75","author":"Ferreira","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026091504191235600_xuag096-B13","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1002\/ejhf.3453","article-title":"The spironolactone initiation registry randomized interventional trial in heart failure with preserved ejection fraction (SPIRRIT-HFpEF): rationale and design","volume":"26","author":"Lund","year":"2024","journal-title":"Eur J Heart Fail"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjhf\/advance-article-pdf\/doi\/10.1093\/ejhf\/xuag096\/70263891\/xuag096.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/28\/3\/535\/70263891\/xuag096.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/28\/3\/535\/70263891\/xuag096.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T08:24:44Z","timestamp":1789460684000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/28\/3\/535\/8744096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":13,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,7,28]]},"published-print":{"date-parts":[[2026,9,15]]}},"URL":"https:\/\/doi.org\/10.1093\/ejhf\/xuag096","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2026,3]]}}}